REGN Regeneron Pharmaceuticals, Inc.

373.45
+3  (1%)
Previous Close 370.37
Open 373.00
Price To book 8.78
Market Cap 39.38B
Shares 105,461,000
Volume 574,429
Short Ratio 2.82
Av. Daily Volume 899,994

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 3Q 2017.
Dupixent (dupilumab)
Atopic dermatitis 6-11 year-olds
Phase 3 trial to be initiated 2Q 2017.
Dupixent (dupilumab)
Atopic dermatitis 12-17 year-olds
Phase 3 data due 4Q 2017.
Praluent (alirocumab) ODYSSEY OUTCOMES
Cardiovascular events
Phase 2 trial to commence 1H 2017.
REGN2810
Non-small cell lung cancer (NSCLC)
Phase 2 trial to commence 1H 2017.
REGN2810
Basal cell carcinoma
Phase 3 data due 2H 2017.
REGN2222
Respiratory syncytial virus (RSV)
Phase 3 trial to be initiated using only lower doses from Phase 2/3 trial.
Fasinumab
Moderate-to-severe osteoarthritis pain of the hip or knee
Phase 3 ongoing.
EYLEA - PROTOCOL-W
Diabetic Retinopathy
Phase 3 ongoing.
EYLEA - PANAROMA
Nonproliferative Diabetic Retinopathy
Phase 3 trial to commence 1Q 2017.
Dupixent (dupilumab)
Asthma - pediatrics
Phase 3 data due 4Q 2017.
Dupixent (dupilumab) - LIBERTY ASTHMA QUEST
Asthma
Phase 3 trial commenced 4Q 2016.
Dupixent (dupilumab)
Nasal polyps
Phase 2b placed on clinical hold. Phase 3 trial to be initiated that excludes patients with advanced osteoarthritis.
Fasinumab
Osteoarthritis and chronic low back pain
Pivotal Phase 2/3 trial ongoing.
REGN2810
Cutaneous squamous cell carcinoma
Phase 2 trial to commence 1H 2017.
REGN2810
Non-small cell lung cancer (NSCLC)
Phase 2 trial to commence 1H 2017.
REGN2810
Basal cell carcinoma
Phase 2 ongoing.
EYLEA + nesvacumab
AMD - age-related macular degeneration
Phase 2 enrollment completed 4Q 2016.
EYLEA + nesvacumab
Diabetic macular edema (DME)
Phase 2 trial to commence in 2017.
Dupixent (dupilumab)
Food Allergy
Phase 2 data due 2H 2017.
Dupixent (dupilumab)
Eosinophilic esophagitis
Approved under priority review - March 28, 2017.
Dupixent (dupilumab)
Atopic dermatitis
CRL October 28, 2016. Resubmission due 1Q 2017 with two month review cycle.
Sarilumab
Rheumatoid arthritis

Latest News

  1. Amgen Trumps Regeneron, Sanofi In Cholesterol Drug Sales
  2. EMA panel recommends nod for Sanofi, Regeneron's arthritis drug
  3. Sanofi Genzyme hit with patent lawsuit over new eczema drug
  4. Lilly and Incyte's Loss Is AbbVie and Regeneron's Gain
  5. 3 Big Reasons to Be Bullish on Biotech Stocks
  6. ($$) As Drug Prices Fall, These Stocks Could Rise
  7. Regeneron to Report First Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2017
  8. Regeneron Pharmaceuticals, Inc. – Value Analysis (NASDAQ:REGN) : April 12, 2017
  9. How These Biotechs Could Save The Drug Sector In Q1 — Or Not
  10. Don't Get Your Hopes Up For Biotech's Q1 Earnings
  11. Blog Coverage Inotek Announces Completion of Recruitment in Phase-2 Study for Glaucoma
  12. Biotech Stock Roundup: Geron Gains on Interim Data, OncoMed Slumps on Pipeline Setback
  13. Generics Set To Weaken This Drugmaker; Can MS Drugs Save It?
  14. Regeneron Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : REGN-US : April 11, 2017
  15. 3 Big Biotech Stocks With Big-Time Catalysts
  16. Regeneron's Evinacumab Gets Breakthrough Therapy by FDA
  17. Regeneron's Evinacumab Gets Breakthrough Designation
  18. Regeneron Science Talent Search to Ring The Nasdaq Stock Market Closing Bell
  19. Regeneron Announces Evinacumab has Received FDA Breakthrough Therapy Designation for Homozygous Familial Hypercholesterolemia (HoFH)
  20. Democrats found a way to speak Trump's language in pharma debate